Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

YOKNEAM, Israel , Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetings Location: Palos Verdes, CA When: Tuesday, Nov. 12 at 2:00 pm PT A live webcast of the presentation can be accessed here.

InMode to Present at Upcoming Investor Conferences

Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war.

InMode: $25/Share Is Closer Than You Think

InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to see value in their products.

InMode: A Deep Dive After Q3 Earnings

InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Sam Eiber - BTIG Operator Good day, and welcome to the InMode's Third Quarter 2024 Earnings Results Conference Call.

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

InMode (INMD) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago.

InMode (INMD) Q3 Earnings and Revenues Beat Estimates

YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024.

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Pomerantz LLP hereby advises investors of recent developments in the class action lawsuit Cement Masons' and Plasterers' Local No. 502 Pension Fund v.

Pomerantz Law Firm Announces Filing Deadline in Class Action Against  InMode Ltd. and Certain Officers – INMD

IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd.

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: InMode (INMD) Q3 Earnings Expected to Decline

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is InMode (INMD) a Great Value Stock Right Now?

Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

AMETEK

Carnival

CrowdStrike

Devon Energy

Eldorado Gold

Emerson Electric

Evolution AB

JFrog

Gap Inc

GRAIL Inc

Intel

iShares U.S. Consumer Goods ETF

Johnson & Johnson

Legend Biotech

Cheniere Energy

NVIDIA

Olaplex Holdings

Ryder System

Regeneron Pharmaceuticals

In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.

Stock Picks From Seeking Alpha's September 2024 New Analysts

YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024.

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

Should Value Investors Buy InMode (INMD) Stock?

InMode's Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs.

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

Are Investors Undervaluing InMode (INMD) Right Now?

YOKNEAM, Israel , Sept. 10, 2024 /PRNewswire/ -- InMode Ltd.

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Present at 2024 Baird Global Healthcare Conference

Q2 2024 revenue was $86.4 million, a 36.5% decrease from Q2 2023. GAAP net income fell to $23.8 million, down from $55.7 million in Q2 2023.

InMode Ltd. Revenue, Profit Plunge

Start Time: 08:30 January 1, 0000 9:07 AM ET InMode Ltd. (NASDAQ:INMD ) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 AM ET Company Participants Moshe Mizrahy - CEO Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - CFO Shakil Lakhani - President, North America Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Miri Segal - CEO, MS-IR Conference Call Participants Danielle Antalffy - UBS Caitlin Cronin - Canaccord Genuity Jeff Johnson - Baird Joseph Conway - Needham and Company Operator Good day, and welcome to InMode's Second Quarter 2024 Earnings Results Conference Call.

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

InMode (INMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.72 per share a year ago.

InMode (INMD) Q2 Earnings and Revenues Top Estimates

YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd.

News for Inmode Ltd Stock (INMD)